Small Cell Lung Cancer

- Introduction

Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer. Although SCLC is characterized by rapid responses to chemotherapy and sensitivity to radiotherapy, due to early treatment resistance, the 5-year overall survival (OS) is <10%. The incidence of SCLC has

decreased in recent decades, and with a prevalence of 1-5 per 10 000 people in the European community (1-4). In Egypt, there was an estimated 375 new cases of SCLC and 335 deaths 

      occurred because of this disease based on GLOBOCAN 2022. (5)